Sravan K. Emany - 31 Jan 2026 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Reporting relationship: Chief Financial Officer
Issuer ticker: BEAM
Reported as of: 31 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2026, 16:05:13 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Bellon, Attorney-in-fact

Key filing fact

Sravan K. Emany filed Form 4 for Beam Therapeutics Inc. (BEAM) on 02 Feb 2026.

Key facts

This page summarizes Sravan K. Emany's Form 4 filing for Beam Therapeutics Inc. (BEAM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001897662 Primary reporting owner

Emany Sravan Kumar

Relationship: Chief Financial Officer
Address: C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Signature date: 02 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BEAM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +63,500
Change %
Price: $0.000000
Shares after: 63,500
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 63,500
Exercise price: $27.62
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.